Literature DB >> 16253816

Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module.

Seung Jun Oh1, Dae Yoon Chi, Christoph Mosdzianowski, Jung Young Kim, Hee Seop Gil, Se Hun Kang, Jin Sook Ryu, Dae Hyuk Moon.   

Abstract

We developed a new fully automated method for the synthesis of [18F]fluoromisonidazole ([18F]FMISO) by modifying a commercial FDG synthesizer and its disposable fluid pathway. A three-step procedure was used to prepare the tosylate precursor, 1-(2'-nitro-1'-imidazolyl)-2-O-tetrahydrofuranyl-3-O-toluenesulfonylpropanediol. Using glycerol as the starting material, the precursor was synthesized with a yield of 21%. The optimal labeling conditions for the automated synthesis of [18F]FMISO was 10 mg of precursor in acetonitrile (2 ml heated at 105 degrees C for 360 s, followed by heating at 75 degrees C for 280 s and hydrolysis with 1 N HCl at 105 degrees C for 300 s. Using 3.7 GBq of [18F]F- as a starting activity, [18F]FMISO was obtained with high end-of-synthesis (EOS) radiochemical yields of 58.5+/-3.5% for 60.0+/-5.2 min with high-performance liquid chromatography (HPLC) purification. When solid-phase purification steps were added, the EOS radiochemical yields were 54.5+/-2.8% (337+/-25 GBq/micromol) for 70.0+/-3.8 min (n=10 for each group, decay-corrected). With a high starting radioactivity of 37.0 GBq, we obtained radiochemical yields of 54.4+/-2.9% and 52.8+/-4.2%, respectively (n=3). The solid-phase purification removed unreacted [18F]fluoride and polar impurities before the HPLC procedure. Long-term tests showed a good stability of 98.2+/-1.5%. This new automated synthesis procedure combines high and reproducible yields with the advantage of using a disposable cassette system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16253816     DOI: 10.1016/j.nucmedbio.2005.06.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  18 in total

1.  ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.

Authors:  Kenji Hirata; Shunsuke Terasaka; Tohru Shiga; Naoya Hattori; Keiichi Magota; Hiroyuki Kobayashi; Shigeru Yamaguchi; Kiyohiro Houkin; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

2.  Changes in tumor oxygen state after sorafenib therapy evaluated by 18F-fluoromisonidazole hypoxia imaging of renal cell carcinoma xenografts.

Authors:  Wenwen Yu; Songji Zhao; Yan Zhao; Chowdhury Nusrat Fatema; Masahiro Murakami; Ken-Ichi Nishijima; Yoshimasa Kitagawa; Nagara Tamaki; Yuji Kuge
Journal:  Oncol Lett       Date:  2017-06-12       Impact factor: 2.967

3.  Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.

Authors:  Nobuyuki Kawai; Wei Lin; Wei-Dong Cao; Daisuke Ogawa; Keisuke Miyake; Reiji Haba; Yukito Maeda; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-30       Impact factor: 9.236

4.  Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.

Authors:  Tomohiko Yamane; Masahiro Kikuchi; Shogo Shinohara; Michio Senda
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 5.  Recent Trends in the Nucleophilic [(18)F]-radiolabeling Method with No-carrier-added [(18)F]fluoride.

Authors:  Dong Wook Kim; Hwan-Jeong Jeong; Seok Tae Lim; Myung-Hee Sohn
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

6.  Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.

Authors:  Maxwell G Handley; Rodolfo A Medina; Erika Mariotti; Gavin D Kenny; Karen P Shaw; Ran Yan; Thomas R Eykyn; Philip J Blower; Richard Southworth
Journal:  J Nucl Med       Date:  2014-01-13       Impact factor: 10.057

7.  Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.

Authors:  Kenta Suzuki; Nobuyuki Kawai; Tomoya Ogawa; Keisuke Miyake; Aya Shinomiya; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2021-07-21       Impact factor: 3.138

8.  Automated radiosynthesis of two 18F-labeled tracers containing 3-fluoro-2-hydroxypropyl moiety, [18F]FMISO and [18F]PM-PBB3, via [18F]epifluorohydrin.

Authors:  Takayuki Ohkubo; Yusuke Kurihara; Masanao Ogawa; Nobuki Nengaki; Masayuki Fujinaga; Wakana Mori; Katsushi Kumata; Masayuki Hanyu; Kenji Furutsuka; Hiroki Hashimoto; Kazunori Kawamura; Ming-Rong Zhang
Journal:  EJNMMI Radiopharm Chem       Date:  2021-07-10

9.  Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma.

Authors:  Toshiyuki Hatano; Songji Zhao; Yan Zhao; Ken-Ichi Nishijima; Norihito Kuno; Hiroko Hanzawa; Takeshi Sakamoto; Nagara Tamaki; Yuji Kuge
Journal:  Int J Oncol       Date:  2013-01-18       Impact factor: 5.650

10.  Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.

Authors:  Masahiro Murakami; Songji Zhao; Yan Zhao; Nusrat Fatema Chowdhury; Wenwen Yu; Ken-Ichi Nishijima; Mitsuyoshi Takiguchi; Nagara Tamaki; Yuji Kuge
Journal:  Int J Oncol       Date:  2012-09-10       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.